Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) were down 2.5% on Thursday . The company traded as low as $2.31 and last traded at $2.37, with a volume of 117,208 shares. The stock had previously closed at $2.43.

A number of analysts recently weighed in on ABEO shares. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 28th. Rodman & Renshaw restated a “buy” rating and set a $17.00 target price on shares of Abeona Therapeutics in a report on Wednesday, April 20th. Maxim Group restated a “buy” rating on shares of Abeona Therapeutics in a report on Tuesday, May 24th. Finally, FBR & Co restated a “buy” rating on shares of Abeona Therapeutics in a report on Wednesday, June 22nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Abeona Therapeutics currently has an average rating of “Buy” and a consensus target price of $11.20.

The stock’s market capitalization is $77.72 million. The company has a 50-day moving average price of $2.74 and a 200-day moving average price of $2.70.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.04. On average, equities research analysts forecast that Abeona Therapeutics Inc. will post ($0.59) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Abeona Therapeutics stock. Royce & Associates LLC raised its stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned approximately 0.92% of Abeona Therapeutics worth $1,007,000 as of its most recent SEC filing.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.